Phenytoin dosage adjustment in Saudi epileptics: utilization of steady-state pharmacokinetic parameters

被引:3
作者
Abduljabbar, M
Al-Khamis, K
Ogunniyi, A
Daif, AK
Al-Yamani, M
机构
[1] King Saud Univ, King Khalid Univ Hosp, Dept Med, Riyadh 11472, Saudi Arabia
[2] King Saud Univ, King Khalid Univ Hosp, Dept Clin Pharm, Riyadh 11472, Saudi Arabia
[3] King Saud Univ, King Khalid Univ Hosp, Dept Pharmacol, Riyadh 11472, Saudi Arabia
关键词
epilepsy; seizures; phenytoin; antiepileptic drugs; pharmacokinetics;
D O I
10.1046/j.1468-1331.1999.630331.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We determined the Michaelis-Menten parameters (V-max and K-m) in 271 Saudi epileptic patients having generalized tonic-clonic seizures and who were treated with phenytoin (PHT) using high pressure liquid chromatography (HPLC). The patients comprised 150 (55.4%) males and 121 (44.6%) females, with a mean age of 31.7 years (SD = 18.5). The mean V-max for subjects less than 16 years of age was 10.35 mg/kg/day (SD = 0.73, range = 3.77-17.01), while for those above 16 years, the mean value was 7.99 mg/kg/day (SD = 0.15, range = 3.68-15.95). The difference was statistically significant (P < 0.001). V-max was positively correlated with weight (r = 0.953), but negative with age (r = -0.903). K-m values ranged from 1.01-20.87 mg/litre. The adult K-m mean of 6.52 mg/l (SD = 0.24) was significantly higher than the mean of 4.79 mg/l (SD = 0.40) for pediatric patients (P < 0.01), but K-m was correlated neither with age nor with weight. Our results showed no difference between the predicted and observed serum PHT concentrations in both the pediatric and adult patients when the respective age group K-m and V-max values were used to adjust PHT doses. The pediatric cases, however, required 30% more PHT per kilogram of body weight than the adults for the achievement of similar serum concentrations. Eur J Neurol 6:331-334 (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:331 / 334
页数:4
相关论文
共 12 条
[1]  
ALKHAMIS KIM, 1995, SAUDI PHARM J, V3, P95
[2]  
ANDOH B, 1980, BRIT J CLIN PHARMACO, V9, P282
[3]   PHENYTOIN MICHAELIS-MENTEN PHARMACOKINETICS IN CAUCASIAN PEDIATRIC-PATIENTS [J].
BAUER, LA ;
BLOUIN, RA .
CLINICAL PHARMACOKINETICS, 1983, 8 (06) :545-549
[4]  
BENET LZ, 1990, PHARMACOL BASIS THER, P3
[5]   Drug therapy - Antiepileptic drugs [J].
Brodie, MJ ;
Dichter, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (03) :168-175
[6]  
CHIBA K, 1980, J PEDIATR-US, V96, P479
[7]  
DOLLERY C, 1991, THERAPEUTIC DRUGS, P93
[8]   ANTICONVULSANT DRUGS - AN UPDATE [J].
EADIE, MJ .
DRUGS, 1984, 27 (04) :328-363
[9]  
ELSAYED YM, 1989, INT J CLIN PHARM TH, V27, P173
[10]   PHENYTOIN AND PHENOBARBITONE PLASMA LEVEL-DOSE RELATIONSHIPS IN CHINESE EPILEPTIC CHILDREN IN SINGAPORE [J].
LEE, HS ;
CHAN, KY .
THERAPEUTIC DRUG MONITORING, 1981, 3 (03) :247-252